Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYR-322 plus pioglitazone versus pioglitazone alone in type 2 diabetes mellitus
2005-004669-40Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing SYR-322 + pioglitazone with Placebo + pioglitazone (2 arms). Primary endpoint: Change from baseline in HbA1c at Week 26. Started Jan 2006; status: completed.
02
Drugs
alogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-004669-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004669-40.